The U.S. Food and Drug Administration (FDA) has granted marketing authorization for Aletta, the first robotic blood draw device authorized for use in adults within outpatient settings. This authorization marks a significant advancement in phlebotomy technology and patient care.

Aletta is designed to support blood collection efficiently, allowing one trained supervisor to oversee up to three devices simultaneously. This capability aims to address shortages of phlebotomists and optimize resource utilization in healthcare facilities.

The FDA's De Novo classification for Aletta underscores the device's novel approach to blood collection and the potential for robotics to complement clinical staffing. The device is expected to enhance operational workflows and maintain patient safety during blood draw procedures.